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Skin cancer is the most common type of cancer. Nation-
wide claims data in the Netherlands were obtained for 
the period 2007–2017 in order to assess the associated 
healthcare costs. Malignant skin tumours were the 4th most 
costly cancer in the Netherlands in 2017, after breast, co-
lorectal, and lung cancer. The total costs for skin tumours 
increased from €278 million for 384,390 patients (in 2007) 
to €465 million for 578,355 patients (in 2017). Drug costs 
increased from €0.7 million to €121 million (over the pe-
riod 2007–17), resulting in a 26% share of overall costs in 
2017. Future total costs for skin cancer are projected to 
reach €1.35 billion in 2030. In conclusion, the increasing 
costs of skin cancer are strongly affected by the increasing 
incidence and introduction of expensive drugs, and future 
projections show an alarming increase.
Skin cancer is the most common type of cancer and its 
incidence is increasing. The objective of this study was 
to describe the trends in reimbursed drug and hospi-
tal costs of benign and (pre)malignant skin tumours, 
and to present future projections. Therefore, nation-
wide hospital and drug reimbursement data (for the 
period 2007–17) were used. In 2017, malignant skin 
tumours were the 4th most costly cancer in the Nether-
lands (after breast, colorectal, and lung cancer). The 
total costs for skin tumours increased from €278 mil-
lion for 384,390 patients (in 2007) to €465 million for 
578,355 patients (in 2017). Drug costs increased from 
€0.7 million to €121 million (over the period 2007–17), 
resulting in a 26% share of overall costs in 2017. Fu-
ture costs are projected to reach €1.35 billion in 2030. 
In conclusion, the increasing costs of skin cancer are 
strongly affected by the increasing incidence and in-
troduction of expensive drugs, and future projections 
are for an alarming increase. 
Key words: skin cancer: skin neoplasm; healthcare costs; 
health expenditure.
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Skin cancer is the most common type of cancer in many Caucasian populations. It results in both a 
high burden and high financial impact (1–3). It is esti-
mated that 1 in 5 persons will develop skin cancer in the 
Netherlands (4). With increasing incidence, the costs of 
management are also expected to rise (3, 5–7).
Knowledge of the healthcare costs related to its main 
components and trends is essential to enable health policy 
decision-makers to make well-informed decisions on po-
tential interventions, and to be able to evaluate the future 
effect of these decisions. Several studies have reported 
skin cancer-related healthcare costs based on estimates for 
different countries. However, these are based on extrapola-
tions of regional data, or are population- (e.g. Medicare), or 
diagnosis-specific (8–11). Furthermore, a comprehensive 
and up-to-date economic evaluation after the introduction 
of expensive drugs for the treatment of skin cancer (i.e. 
targeted therapy and immunotherapy) is lacking. 
The primary objective of this study was to describe 
national trends of reimbursed drug and hospital costs of 
benign, premalignant and malignant skin tumours over 
the past 11 years, and to compare the costs for malignant 
skin tumours with other malignancies in the Netherlands. 
Secondary objectives were to evaluate the proportion 
attributable to benign and malignant tumours, the dist-
ribution of the costs across different medical specialties, 
and the effect of the introduction of expensive drugs on 
the overall healthcare costs related to cutaneous malig-
nancies. Furthermore, taking into account the expected 
increasing financial burden of skin cancer management, 
this study projected the current costs to 2030, based on 
published trends in incidence rates.
MATERIALS AND METHODS
Data source
The economic burden of skin tumour management was studied 
from a healthcare perspective using a top-down approach. Only 
reimbursed direct medical hospital care costs were investigated. 
Indirect and primary care costs were not included. 
Nationwide data concerning reimbursed hospital and drug costs 
were obtained from Vektis, a central database collecting data on all 
reimbursed healthcare claims in the Netherlands; previous valida-
tion showed an overall accuracy of over 95% (12). Since 2006, the 
Dutch healthcare system has been based on a single compulsory 
insurance scheme (i.e. Health Insurance Act) (13). Reimbursement 
is based on a Diagnosis Related Groups (DRGs) system, in which 
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all activities related to diagnosing or treating patients are included, 
resulting in a reimbursement claim. 
Data extraction
All drug and DRG claims for all medical specialties contributing to 
the treatment of benign, premalignant and malignant skin tumours 
in the period 2007–17 were included (Table SI1). These DRG 
claims comprise all possible benign, premalignant and malignant 
skin tumours. Hospital claims data includes both inpatient as well 
as outpatient care. Data were aggregated such that the number 
of claims, unique number of patients (i.e. the number of patients 
with at least one relevant claim), year, costs, and mean costs were 
available. Also, information was obtained on Anatomical Thera-
peutic Chemical (ATC) classification codes of drugs related to 
skin tumour treatments, including the number of claims, number 
of patients, year, total and mean costs. In the Dutch healthcare 
system, drugs are divided into regular pharmaceuticals (relative 
low-cost) and add-on pharmaceuticals (relative high-cost) (Table 
SII1). Add-on pharmaceuticals are provided in an inpatient setting, 
although they were charged separately from DRGs. Both low-cost 
and high-cost drugs were included in the analyses. 
Analysis of the cost-drivers for skin cancer management focused 
merely on skin cancer management costs in dermatology, as DRGs 
are less specific for skin cancer in other medical specialties. The 
health care products with their accompanying costs were aggregat-
ed into the following groups: diagnostic evaluations, outpatient 
visits, inpatient care, operative treatment, non-operative treatment, 
and other. This data was available for the period 2012–17.
In order to obtain a perspective on the scope of the economic 
burden of skin cancer management compared with all cancer types, 
claims for direct medical costs of all malignancies and medical 
specialties were extracted (Table SIII1).
Statistical analyses
No hypothesis testing and sample size calculations were perfor-
med. The costs were adjusted to 2018 Euros by using consumer 
price index inflation rates from StatBureau (www.statbureau.org). 
The descriptive analyses were performed using SPSS 24.0 (SPSS 
Inc., Chicago, IL, USA). 
Future projections for the reimbursed costs for skin tumours 
to 2030 were based on published estimates of incidence growth 
rates for basal cell carcinomas (BCCs), squamous cell carcinoma 
(SCCs) and melanomas (2, 14–16). The unique number of patients 
in 2017 was used to extrapolate future incidence based on an 
annual increasing incidence rate of 5% (scenario A). The annual 
incidence rates were multiplied by the mean costs per patient of 
2017, including future annual inflation rates of 2% from the Or-
ganisation for Economic Co-operation and Development (OECD) 
inflation forecast (17). Furthermore, future costs (up to 2 years) 
for the market entry of new innovative drugs and broadening in-
dications of existing drugs, as publicly published by Horizonscan, 
were also taken into account (18). 
Sensitivity analyses
Compared with dermatology, for some medical specialties such 
as (plastic) surgery, ear, nose and throat (ENT) and radiotherapy, 
claims data are less specific for skin cancer management. For 
example, a plastic surgery DRG claim may concern both skin 
tumours and skin infections. Therefore, we performed a sensitivity 
analysis, in which 50% of the costs for non-specific claims (Table 
SI1) were included compared with 100% in the main analyses. 
This limit was chosen with the assumption that at least half of 
the included claims concerned skin cancer. Drug reimbursement 
costs were excluded from the sensitivity analysis, as these are not 
specific for a specialty. Given the unknown future trends in inci-
dence rates 2 sensitivity analyses were performed for predicting 
the future costs: scenario B, an annual increasing incidence rate of 
10%; and scenario C, stabilization with flattening of the incidence 
of skin cancer.
RESULTS
The total annual costs for benign, premalignant and 
malignant skin tumour management (including drug and 
hospital care) increased from €278 million for 384,390 
patients in 2007 to €465 million for 578,355 patients in 
2017 (Fig. 1). The mean costs per patient for benign, 
premalignant and malignant skin tumour management in-
creased from €723 to €804 during the period 2007–2017. 
Malignant tumours show a higher mean annual cost 
per patient for hospital care compared with prema-
lignant and benign tumours and naevi. For malignant 
skin tumours the mean annual costs per patient show 1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3463
Fig. 1. Total annual costs of skin tumours (i.e. benign, 
in situ and malignant) for drugs and medical specialist 
care, vs the number of unique patients, 2007–2017. 
The relative trough level in 2015 was caused by shortening 
of the Diagnosis Related Group duration in 2015, causing 
artificially lower costs.Year
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an upward trend between 2007 and 2012 (i.e. 35% in-
crease), while a downward trend is seen during the last 
5 years (i.e. 20% decrease). In contrast to the decreasing 
mean annual costs per patient, the total annual costs for 
malignant skin tumours continue to increase, resulting 
from increasing incidence. In 2017, the annual costs of 
malignant skin tumours comprise 60% of the total skin 
tumour expenditure (€112.7/€188 in millions), represent-
ing 44% of all patients with skin tumours in dermatology 
(221,307/505,555). 
Costs for skin tumour management per treating medical 
specialty
In 2017, the costs for dermatological skin tumour ma-
nagement were €188 million (comprising 85% of all 
patients with skin tumours and 56% of the total costs), 
whereas the total costs for other specialties remained 
below €50 million. Internal medicine is the most costly 
per patient, treating 0.5% of all patients with annual 
mean costs per patient increasing from €3,759 in 2007 
to €7,085 in 2017. The total costs in 2017 for internal 
medicine comprised 6% of the total skin tumour-related 
hospital care costs. 
Cost-drivers in skin cancer management
With the introduction of new agents, in particular for 
the treatment of advanced and metastatic melanoma, 
drug costs comprise an increasing part of the healthcare 
costs. The total drug costs increased from €0.7 million 
(2007) to €121 million (2017). The main contribution 
to the increase in the total drug costs concerned add-on 
pharmaceuticals, being €118 million in 2017 (Fig. 1) (for 
8,351 users). The total costs for regular drugs increased 
from €0.7 million (2007; for 10,305 users) to €2.5 mil-
lion (2017; for 45,662 users). 
Excluding drug costs, the largest cost-drivers for 
the total costs of dermatological skin cancer manage-
ment regarding premalignant and malignant tumours 
(€153/€188) were operative treatments, comprising 67% 
of the total costs in 2017 (Fig. 2). The next main cost-
drivers were outpatient visits (26%) and non-operative 
treatments (6%).
Costs of skin cancer compared with other cancers
The direct hospital costs of malignant skin tumour ma-
nagement comprised €244 million in 2017, making it 
the 4th most costly cancer in the Netherlands, with breast 
Fig. 2. Cost-drivers of skin cancer 
management (premalignant and malignant 
tumours) in dermatology medical specialist 
care, 2012–2017.Total annual costs (euros x 1 000 000)

















Table I. The top 10 most costly cancers, both invasive and in situ, 
in the Netherlands (2017) based on direct costs of hospital care
Type of cancer Total costs (in million €)
Breast cancer  473
Colorectal cancer  368
Lung cancer  299
Skin cancer  244
Leukaemias  204
Renal and kidney cancer  148
Cancer of the brain and nervous system  137 
Prostate cancer  128
Hodgkin/non-Hodgkin lymphomas  118
Cancer of the bladder  114
Years


























Future projection with incidence rate increasing with 5% 
Future projection with incidence rate remaining stable 
Future projection with incidence rate increasing with 10% 
Fig. 3. Future projects of the reimbursed costs for benign, 
premalignant and malignant skin tumour management out to 
2030, based on 3 scenarios. The analyses with an annual 5% increasing 
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cancer, colorectal cancer and lung cancer being more 
costly (Table I). 
Projections to 2030
The reimbursed costs for benign, premalignant and ma-
lignant skin tumour management are projected to be €681 
million in 2020, €959 million in 2025 and €1.35 billion 
in 2030, for the scenario based on an annual increase in 
incidence rate of 5% (Fig. 3).
Sensitivity analyses
The observed difference between the main and sensitivity 
analyses for total direct hospital costs was €27.7 million 
(8%) in 2017, with total costs for medical specialist care 
being €317 million in 2017 compared with €345 mil-
lion in the main analyses. The sensitivity analyses for 
the future costs projections showed that, with a stable 
incidence rate, the overall costs would increase up to 
€602 million by 2030 due to inflation, compared with 
€465 million in 2017 (Fig. 3). The overall costs could 
be as high as €2.1 billion by 2030, with incidence rates 
increasing by 10% annually. 
DISCUSSION
This study provides up-to-date quantified data on 
reimbursed drug and hospital care costs of skin tumour 
management and presents trends over the past decade in 
the Netherlands. Skin cancer is the 4th most costly cancer 
in the Netherlands, and is strongly affected by its increa-
sing incidence and the introduction of expensive drugs. 
As expected, reimbursement costs for malignant skin 
tumours are both in total and per patient higher than for 
benign skin tumours. Large differences were observed in 
hospital care costs for skin tumour management among 
different medical specialties. Whereas internal medicine 
was the most costly per patient, although covering a small 
volume, dermatology was one of the least costly per pa-
tient, although with the highest volume. The high costs 
for internal medicine are the result of the introduction of 
expensive (add-on) drugs, including immunotherapy and 
targeted therapy, for treatment of advanced and metastatic 
skin cancer, in particular melanoma. 
Taking costly (add-on) drug costs into account, the 
total annual skin tumour costs increased by 67%, with a 
50% increase in total patient volume over the last decade. 
Drug costs represented 26% (€121/€465 million) of the 
total costs in 2017, and 0.3% (€0.7/€278 million) in 2007. 
This reflects the increasingly important role of pharma-
ceutical treatment in the management of skin cancer, 
especially with the introduction of new drugs. Another 
example contributing to the increasing role of drugs in 
skin cancer management involves the restricted reim-
bursement for photodynamic therapy since 2013 in the 
Netherlands. This resulted from studies demonstrating 
that inexpensive treatments, such as topical 5-fluorura-
cil and imiquimod, are non-inferior or even superior to 
photo dynamic therapy for superficial BCC (19, 20). 
When comparing different specialties, the mean an-
nual reimbursed costs per patient for internal medicine is 
striking; an evident increase was observed after an initial 
decrease in 2011–12 (data not shown). This downfall may 
be largely attributable to Dutch participation in several 
clinical trials on BRAF-inhibition and checkpoint inhibi-
tion for advanced and metastatic melanoma (21–27). As 
these trials are sponsored by pharmaceutical companies, 
the costs are not included in the insurance registry data. 
After the approval and reimbursement of ipilimumab 
in 2012, additional expensive agents were approved, 
leading to increasing mean annual costs for internal 
medicine. In addition to the drug costs, treatment with 
these new agents is associated with other costs including 
frequent hospital visits, extensive diagnostics (i.e. labora-
tory tests and imaging), and management of drug-induced 
toxicities (10, 28). As a result of the potential high ef-
ficacy and durable systemic treatment for melanoma, it 
is expected that these costs will further increase with the 
expanding use of expensive drugs (for example, adjuvant 
therapy) for stage III melanoma (18, 29).
Several previous studies have estimated the costs as-
sociated with skin cancer management (8, 11, 30–32). 
However, in contrast to our study, these studies extra-
polated the costs according to national incidence or 
prevalence data, or are subtype specific (i.e. melanoma). 
Furthermore, with the lack of formal registries of SCCs 
and BCCs in many countries, this creates further uncer-
tainty and making direct comparisons difficult (2).
The rationale for restructuring the healthcare system 
in 2006 was to implement a system in which healthcare 
expenditures would become more controllable (33). Re-
gardless of this restructuring, the healthcare expenditures 
continue to increase (33–35). This also applies to skin 
cancer: although the mean costs per patient in dermato-
oncological care decreased, the overall expenditures in-
creased. This has 2 main reasons: the increasing number 
of patients (1.5-fold increase) and therefore increasing 
use of healthcare services, and the increase in supply of 
healthcare services with the development of new (expen-
sive) drugs. Our future projection, which is based solely 
on a 5% increasing incidence rate and inflation, shows the 
costs increasing to €1.35 billion by 2030. Although this 
excludes a further price-effect by new drugs introduced 
in the future, and an additional volume-effect by broade-
ning indications of pharmaceutical treatment, it already 
shows an alarming increase in overall costs. 
Considering the increasing costs of skin cancer ma-
nagement, and the fact that the majority of skin cancers 
are preventable, there is considerable potential regarding 
efficient prevention. Several skin cancer prevention pro-
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paign, ban on sunbed use) may be cost-effective and also 
cost saving for governments (8, 30, 36), but until now 
prevention strategies initiated by the Dutch government 
have been restricted. In recent years, the Dutch Cancer 
Society (KWF) initiated more active campaigning on the 
prevention of skin cancer, although it focusses mainly 
on sun-tanning behaviour (37). We therefore believe that 
governments should play a larger role in initiating and 
supporting major public health campaigns for skin cancer 
prevention, more similar to that of tobacco control. With 
our study showing drug reimbursement costs contributing 
substantially to the total cost of skin tumour management, 
this is a key element for health policymakers. 
Although the database used comprises a high sensiti-
vity due to the obligatory aspect of registering DRGs, the 
described reimbursed healthcare may, however, still be an 
underestimation for 3 main reasons. Drug reimbursement 
costs were not provided by Vektis when the number of 
users was fewer than 10, as this may distort competi-
tion in the price negotiations between insurers and care 
providers. Secondly, drugs provided in a trial setting are 
not registered by insurers, and thus not included in our 
study. Finally, patients receiving a skin examination as a 
secondary healthcare request during other health-related 
visits may have not been recorded, although this amount 
is probably small due to a financial incentive for com-
plete registration. Benign tumours were included in the 
evaluation of the total reimbursed costs for skin tumour 
management, as they may initially appear malignant, for 
which referral to secondary care is warranted. This may 
have resulted in a small overestimation of the economic 
burden.
Inherent to the design of our study, the primary care 
costs and indirect costs of skin tumour management were 
not included, since this information is not recorded by 
health insurance companies. Previous studies have shown 
indirect costs in skin tumour management to be lower 
compared with other types of cancer, due to a relatively 
low amount of production loss (38–40). 
Since the claims system was not developed for re-
search purposes, our study has some limitations. Medical 
specialties other than dermatology have a less specific 
coding system regarding skin tumour management, due 
to which we were unable to differentiate the costs bet-
ween, for example, costs attributable to melanoma and 
non-melanoma skin cancer. This may also create some 
uncertainty regarding the specificity of the costs associa-
ted with skin cancer. Our sensitivity analysis showed this 
uncertainty to be 8% (€27.7 million) for 2017. 
In conclusion, the results of this study shows that the 
hospital care costs for skin tumour management are 
increasing steeply, with skin cancer being the 4th most 
costly cancer in the Netherlands. As the affordability of 
healthcare is pivotal, hospital costs are under pressure. 
The increasing costs seem to be affected mainly by the 
introduction of expensive drugs, emphasizing the need 
for controlling drug costs by, for example, effective 
price negotiations. In addition, increasing skin cancer 
incidence contributed to the increasing costs, providing 
a potential target for intervention. The government has 
an important role in supporting and initiating effective 
prevention campaigns.
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